Stock Research for ECYT


Featured Broker: Ally Invest

Get the due diligence for another stock.


ECYT Stock Chart & Research Data

The ECYT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ECYT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ECYT Due diligence Resources & Stock Charts

The ECYT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ECYT Detailed Price Forecast - CNN Money CNN View ECYT Detailed Summary - Google Finance
Yahoo View ECYT Detailed Summary - Yahoo! Finance Zacks View ECYT Stock Research & Analysis -

Stock Analysis

TradeIdeas View ECYT Trends & Analysis - Trade-Ideas Barrons View ECYT Major Holders - Barrons
NASDAQ View ECYT Call Transcripts - NASDAQ Seeking View ECYT Breaking News & Analysis - Seeking Alpha
Spotlight View ECYT Annual Report - OTC Report View ECYT OTC Short Report -
TradeKing View ECYT Fundamentals - TradeKing Charts View ECYT SEC Filings - Bar Chart
WSJ View Historical Prices for ECYT - The WSJ Morningstar View Performance/Total Return for ECYT - Morningstar
MarketWatch View the Analyst Estimates for ECYT - MarketWatch CNBC View the Earnings History for ECYT - CNBC
StockMarketWatch View the ECYT Earnings - StockMarketWatch MacroAxis View ECYT Buy or Sell Recommendations - MacroAxis
Bullish View the ECYT Bullish Patterns - American Bulls Short Pains View ECYT Short Pain Metrics -

Social Media Mentions

StockTwits View ECYT Stock Mentions - StockTwits PennyStocks View ECYT Stock Mentions - PennyStockTweets
Twitter View ECYT Stock Mentions - Twitter Invest Hub View ECYT Investment Forum News - Investor Hub
Yahoo View ECYT Stock Mentions - Yahoo! Message Board Seeking Alpha View ECYT Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ECYT - Insider Cow View Insider Transactions for ECYT - Insider Cow
CNBC View ECYT Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ECYT - OTC Markets
Yahoo View Insider Transactions for ECYT - Yahoo! Finance NASDAQ View Institutional Holdings for ECYT - NASDAQ

Stock Charts

FinViz View ECYT Stock Insight & Charts - StockCharts View ECYT Investment Charts -
BarChart View ECYT Stock Overview & Charts - BarChart Trading View View ECYT User Generated Charts - Trading View

Latest Financial News for ECYT

Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)
Posted on Friday May 18, 2018

The meeting hasn't even started, and stocks are already moving.

Blog Exposure - FDA Accepted for Review Insmed’s Marketing Application for ALIS in NTM Lung Disease Caused by MAC
Posted on Friday May 18, 2018

LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want access to our free research report on Insmed Inc. (NASDAQ: INSM), all you need to do is sign up now by clicking the following link as the Company's latest news hit the wire. On May 16, 2018, the Company announced that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ALIS (Amikacin Liposome Inhalation Suspension) for treatment of adult patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Should You Be Concerned With Endocyte Inc’s (NASDAQ:ECYT) -15.38% Earnings Drop?
Posted on Thursday May 17, 2018

For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Endocyte Inc’s (NASDAQ:ECYT) track record on a high level, to giveRead More...

Endocyte Announces Presentation of Phase 2 Data from Investigator-Initiated Prostate Cancer Trial of 177Lu-PSMA-617 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Posted on Wednesday May 16, 2018

Endocyte, Inc. (ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that a poster with data from the Peter MacCallum Cancer Centre will be presented on Endocyte’s lead investigational therapy at the 2018 ASCO Annual Meeting on Saturday, June 2, 2018. Updated data from the phase 2 study of 177Lu-PSMA-617 as a potential treatment for metastatic castration-resistant prostate cancer (mCRPC), including data from an additional 20 patient expansion cohort, will be highlighted by the poster. “We are very pleased that we continue to see high rates of PSA response, even in heavily pre-treated patients,” said Mike Sherman, president and CEO of Endocyte.

Enter a stock symbol to view the stock details.